Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | CSF1R | P07333 | 5/20 | 0.57 |
| ▸ | NAMPT | P43490 | 4/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214172 | 0.80 | CSF1R (0.83) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL13765874 | 0.80 | CSF1R (0.76) | NPC1CSF1RNAMPT | |
| SCHEMBL13455618 | 0.79 | NAMPT (0.67) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL14627247 | 0.77 | NPC1 (0.81) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL13455669 | 0.77 | NPC1 (0.68) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL3203522 | 0.77 | NAMPT (0.72) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL3208864 | 0.76 | GRM5 (0.53) | MAPT | |
| SCHEMBL5805696 | 0.76 | PTGDR2 (0.40) | CSF1RGAAALDH1A1MAPTRET | |
| SCHEMBL13765780 | 0.75 | CSF1R (0.71) | NPC1CSF1RNAMPTCYP11B2CYP11B1 | |
| SCHEMBL1921254 | 0.74 | TSHR (0.52) | NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | NPC1 2916/4885CSF1R 4319/4885NAMPT 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.